Showing results (421-430 of 760) with videos related to

Sort By:
Pageof 76
Blood|July 10, 2009
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significanceSimona Blotta, Pierfrancesco Tassone, Rao H Prabhala, et al.
The Journal of Biological Chemistry|December 17, 2002
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cellsKlaus Podar, Yu-Tzu Tai, Craig E Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myelomaMariateresa Fulciniti, Teru Hideshima, Claudine Vermot-Desroches, et al.
Blood|October 27, 2023
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myelomaJooeun Bae, Shuichi Kitayama, Zach Herbert, et al.
Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.
The Journal of Clinical Investigation|March 5, 2013
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progressionAldo M Roccaro, Antonio Sacco, Patricia Maiso, et al.
British Journal of Haematology|April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Blood|December 3, 2003
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentKlaus Podar, Laurence P Catley, Yu-Tzu Tai, et al.
Pageof 76